Anticancer Peptides advanced
Carfilzomib Proteasome Inhibitor
Irreversible epoxyketone proteasome inhibitor derived from natural product epoxomicin for multiple myeloma treatment.
By Encyclopeptide Editorial | 1 min read
carfilzomib proteasome epoxyketone multiple-myeloma cancer
Chemical Identity
| Property | Value |
|---|---|
| Chemical Formula | C40H57N5O7 |
| Molecular Weight | 719.9 Da |
| CAS Number | 868526-25-2 |
| Product Name | Kyprolis |
| Mechanism | Irreversible proteasome inhibitor |
Structure
Carfilzomib is a tetrapeptide epoxyketone derived from the natural product epoxomicin. The epoxyketone warhead forms an irreversible covalent bond with the N-terminal threonine of the 20S proteasome.
Clinical Applications
- Multiple myeloma (relapsed/refractory)
- Often used in combination with dexamethasone or lenalidomide
- CARFILZOMIB demonstrated superiority over bortezomib in some settings
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Carfilzomib Proteasome Inhibitor” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Carfilzomib Proteasome Inhibitor with interactive quizzes on Wikipept.
Take a Quiz on Wikipept